193 related articles for article (PubMed ID: 35700044)
1. The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy.
Mohsenzadegan M; Nowroozi MR; Fotovvat A; Bavandpour Baghshahi P; Bokaie S; Inanloo SH; Sharifi L
Scand J Immunol; 2022 Sep; 96(3):e13197. PubMed ID: 35700044
[TBL] [Abstract][Full Text] [Related]
2. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer.
Mohsenzadegan M; Bavandpour P; Nowroozi MR; Amini E; Kourosh-Arami M; Momeni SA; Bokaie S; Sharifi L
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2131-2146. PubMed ID: 33745426
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
5. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
7. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
8. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
9. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Carlo MI; Voss MH; Motzer RJ
Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
[TBL] [Abstract][Full Text] [Related]
11. The immunology of renal cell carcinoma.
Díaz-Montero CM; Rini BI; Finke JH
Nat Rev Nephrol; 2020 Dec; 16(12):721-735. PubMed ID: 32733094
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
13. Tim-3 finds its place in the cancer immunotherapy landscape.
Acharya N; Sabatos-Peyton C; Anderson AC
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601081
[TBL] [Abstract][Full Text] [Related]
14. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.
Tian J; Luo J; Zeng X; Ke C; Wang Y; Liu Z; Li L; Zhang Y; Hu Z; Yang C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38355278
[TBL] [Abstract][Full Text] [Related]
15. Role of immunotherapy in kidney cancer.
Nazzani S; Bazinet A; Karakiewicz PI
Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
[TBL] [Abstract][Full Text] [Related]
16. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
17. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
Hah YS; Koo KC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
[TBL] [Abstract][Full Text] [Related]
18. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
19. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
[TBL] [Abstract][Full Text] [Related]
20. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.
Xu Y; Miller CP; Warren EH; Tykodi SS
Hum Vaccin Immunother; 2021 Jul; 17(7):1882-1896. PubMed ID: 33667140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]